599.10
+21.20
+(3.67%)
At close: January 15 at 5:32:06 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 47 | 35 | 66 | 65 |
| Avg. Estimate | 46.97B | 41.79B | 162.97B | 186.63B |
| Low Estimate | 45.73B | 40.54B | 160.28B | 179.84B |
| High Estimate | 47.85B | 43.5B | 164.13B | 195.41B |
| Year Ago Sales | 40.11B | 36.45B | 134.9B | 162.97B |
| Sales Growth (year/est) | 17.10% | 14.65% | 20.81% | 14.51% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| META.VI | -- | -- | -- | -- |
| S&P 500 | 8.43% | 11.29% | 13.87% | 13.50% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/30/2024 |
| Maintains | Monness, Crespi, Hardt: Buy to Buy | 9/30/2024 |
| Maintains | Rosenblatt: Buy to Buy | 9/26/2024 |
| Maintains | B of A Securities: Buy to Buy | 9/26/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 9/26/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 9/26/2024 |